Stonebridge Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-32,123
| Closed | -$1.91M | – | 99 |
|
|
2022
Q1 | $1.91M | Sell |
32,123
-350
| -1% | -$22.4K | 0.69% | 39 |
|
|
2021
Q4 | $2.36M | Sell |
32,473
-2,900
| -8% | -$200K | 0.82% | 34 |
|
|
2021
Q3 | $2.47M | Sell |
35,373
-690
| -2% | -$48.5K | 0.91% | 32 |
|
|
2021
Q2 | $2.48M | Buy |
36,063
+200
| +0.6% | +$13.4K | 0.9% | 33 |
|
|
2021
Q1 | $2.32M | Buy |
35,863
+1,300
| +4% | +$83.8K | 0.88% | 33 |
|
|
2020
Q4 | $2.01M | Sell |
34,563
-72
| -0.2% | -$4.34K | 0.83% | 34 |
|
|
2020
Q3 | $2.19M | Buy |
34,635
+6,255
| +22% | +$434K | 1.01% | 31 |
|
|
2020
Q2 | $2.16M | Sell |
28,380
-2,268
| -7% | -$174K | 1.11% | 30 |
|
|
2020
Q1 | $2.29M | Sell |
30,648
-1,800
| -6% | -$124K | 1.28% | 25 |
|
|
2019
Q4 | $2.11M | Sell |
32,448
-6,335
| -16% | -$413K | 0.92% | 34 |
|
|
2019
Q3 | $2.46M | Sell |
38,783
-15,455
| -28% | -$1.01M | 1.14% | 27 |
|
|
2019
Q2 | $3.66M | Sell |
54,238
-22,319
| -29% | -$1.47M | 1.44% | 19 |
|
|
2019
Q1 | $4.98M | Buy |
76,557
+6,626
| +9% | +$440K | 1.82% | 18 |
|
|
2018
Q4 | $4.38M | Buy |
69,931
+8,356
| +14% | +$584K | 1.75% | 19 |
|
|
2018
Q3 | $4.75M | Sell |
61,575
-985
| -2% | -$74.4K | 1.63% | 20 |
|
|
2018
Q2 | $4.55M | Buy |
62,560
+11,615
| +23% | +$820K | 1.63% | 21 |
|
|
2018
Q1 | $3.83M | Sell |
50,945
-2,730
| -5% | -$217K | 1.4% | 24 |
|
|
2017
Q4 | $4.24M | Buy |
53,675
+11,880
| +28% | +$902K | 1.51% | 23 |
|
|
2017
Q3 | $3.39M | Sell |
41,795
-11,315
| -21% | -$865K | 1.27% | 25 |
|
|
2017
Q2 | $3.76M | Sell |
53,110
-8,570
| -14% | -$570K | 1.44% | 22 |
|
|
2017
Q1 | $4.19M | Buy |
61,680
+6,450
| +12% | +$454K | 1.69% | 19 |
|
|
2016
Q4 | $3.96M | Buy |
55,230
+430
| +0.8% | +$32K | 1.67% | 19 |
|
|
2016
Q3 | $4.34M | Buy |
54,800
+26,040
| +91% | +$2.12M | 1.86% | 20 |
|
|
2016
Q2 | $2.4M | Buy |
28,760
+6,290
| +28% | +$558K | 1.09% | 30 |
|
|
2016
Q1 | $2.06M | Buy |
22,470
+14,530
| +183% | +$1.31M | 0.88% | 32 |
|
|
2015
Q4 | $803K | Buy |
7,940
+800
| +11% | +$83.2K | 0.34% | 57 |
|
|
2015
Q3 | $701K | Buy |
7,140
+725
| +11% | +$80.5K | 0.32% | 60 |
|
|
2015
Q2 | $751K | Buy |
6,415
+1,805
| +39% | +$197K | 0.31% | 69 |
|
|
2015
Q1 | $452K | Hold |
4,610
| – | – | 0.18% | 107 |
|
|
2014
Q4 | $435K | Sell |
4,610
-500
| -10% | -$51.7K | 0.17% | 115 |
|
|
2014
Q3 | $544K | Buy |
5,110
+10
| +0.2% | +$979 | 0.21% | 98 |
|
|
2014
Q2 | $423K | Buy |
+5,100
| New | +$397K | 0.16% | 120 |
|
Other funds holding GILD
Stonebridge Capital Management's GILD Position: Q2 2022 in Review
Stonebridge Capital Management sold out of Gilead Sciences (GILD) in Q2 2022, closing a stake of 32,123 shares — an estimated $1.91M sold.
Stonebridge Capital Management first reported a position in GILD in Q2 2014 and held it in 32 quarters. The position peaked at $4.98M in Q1 2019. 1,603 funds tracked by Wall St. Rank hold GILD as of Q2 2022.
- Stonebridge Capital Management reported no remaining Gilead Sciences position as of Q2 2022 after selling out during the quarter.
- Stonebridge Capital Management sold 32,123 Gilead Sciences shares in Q2 2022, an estimated $1.91M.
- Stonebridge Capital Management first reported a position in Gilead Sciences in Q2 2014 and held it in 32 quarters.
- Stonebridge Capital Management's Gilead Sciences position peaked at $4.98M in Q1 2019.
- 1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2022.
Based on Stonebridge Capital Management's 13F filing for Q2 2022, filed 1 Jul 2022.